EP3624810A4 - Nano-aktivierte immuntherapie bei krebserkrankungen - Google Patents

Nano-aktivierte immuntherapie bei krebserkrankungen Download PDF

Info

Publication number
EP3624810A4
EP3624810A4 EP18803111.6A EP18803111A EP3624810A4 EP 3624810 A4 EP3624810 A4 EP 3624810A4 EP 18803111 A EP18803111 A EP 18803111A EP 3624810 A4 EP3624810 A4 EP 3624810A4
Authority
EP
European Patent Office
Prior art keywords
immunotherapy
nano
cancer
enabled
enabled immunotherapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP18803111.6A
Other languages
English (en)
French (fr)
Other versions
EP3624810A1 (de
Inventor
E. Andre NEL
Huan MENG
Jianqin LU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Publication of EP3624810A1 publication Critical patent/EP3624810A1/de
Publication of EP3624810A4 publication Critical patent/EP3624810A4/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Nanotechnology (AREA)
  • Botany (AREA)
  • Biophysics (AREA)
  • Ceramic Engineering (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP18803111.6A 2017-05-18 2018-05-17 Nano-aktivierte immuntherapie bei krebserkrankungen Pending EP3624810A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762507996P 2017-05-18 2017-05-18
US201862614325P 2018-01-05 2018-01-05
PCT/US2018/033265 WO2018213631A1 (en) 2017-05-18 2018-05-17 Nano-enabled immunotherapy in cancer

Publications (2)

Publication Number Publication Date
EP3624810A1 EP3624810A1 (de) 2020-03-25
EP3624810A4 true EP3624810A4 (de) 2021-02-17

Family

ID=64274728

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18803111.6A Pending EP3624810A4 (de) 2017-05-18 2018-05-17 Nano-aktivierte immuntherapie bei krebserkrankungen

Country Status (4)

Country Link
EP (1) EP3624810A4 (de)
AU (1) AU2018269742B2 (de)
CA (1) CA3063932A1 (de)
WO (1) WO2018213631A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10682400B2 (en) 2014-04-30 2020-06-16 President And Fellows Of Harvard College Combination vaccine devices and methods of killing cancer cells
JP7138864B2 (ja) 2016-02-06 2022-09-20 プレジデント アンド フェローズ オブ ハーバード カレッジ 免疫を再構成するための造血ニッチの再現
US11555177B2 (en) 2016-07-13 2023-01-17 President And Fellows Of Harvard College Antigen-presenting cell-mimetic scaffolds and methods for making and using the same
US11433143B2 (en) 2017-05-18 2022-09-06 The Regents Of The University Of California Nano-enabled immunotherapy in cancer
EP3860622A4 (de) * 2018-10-01 2022-06-29 The Regents of the University of California Verfahren zur behandlung von krebs mit doppelsträngigen rna-sensoraktivatoren und adoptiver zelltherapie
EP3976062A4 (de) * 2019-05-30 2023-06-14 The Board Of Trustees Of The University Of Illinois Procaspase-3-aktivierung und immuntherapie zur behandlung von krebs
CN110585131A (zh) * 2019-09-20 2019-12-20 宁夏医科大学 共载化疗药物的1-甲基色氨酸免疫前药胶束、制备方法及其应用
EP4034148A1 (de) * 2019-09-23 2022-08-03 President and Fellows of Harvard College Biomaterialbasierter antigenfreier impfstoff und verwendung davon
CA3157508A1 (en) * 2019-10-14 2022-04-22 The Regents Of The University Of California Nano-enabled immunotherapy in cancer
JP2023502182A (ja) 2019-11-12 2023-01-20 ナミ セラピューティクス， インコーポレイテッド がんの処置において有用なｉｄｏアンタゴニストプロドラッグを含有する製剤化および／または共製剤化されたリポソーム組成物およびその方法
CN111333653A (zh) * 2019-12-16 2020-06-26 山东大学 一种icd诱导剂-ido抑制剂缀合物及制备方法与应用
WO2021126281A1 (en) 2019-12-20 2021-06-24 Nammi Therapeutics, Inc. Formulated and/or co-formulated liposome compositions containing toll-like receptor ("tlr") agonist prodrugs useful in the treatment of cancer and methods thereof
CN111012919B (zh) * 2019-12-23 2021-06-01 山东大学 聚乙二醇化的icd诱导剂-ido抑制剂纳米缀合物及制备方法与应用
WO2021133037A1 (ko) * 2019-12-26 2021-07-01 연세대학교 산학협력단 피롤리딘 유도체 및 이를 포함하는 베타-아밀로이드 또는 타우 단백질 관련 질병의 예방 또는 치료용 약학 조성물
JP2023514324A (ja) 2020-02-19 2023-04-05 ナミ セラピューティクス， インコーポレイテッド がんの処置において有用なＴＦＧβアンタゴニストプロドラッグを含有する製剤化および／または共製剤化リポソーム組成物ならびにその方法
CN111330004B (zh) * 2020-03-04 2023-02-10 中国人民解放军军事科学院军事医学研究院 二硫化钼纳米片层在制备树突状细胞功能促进剂中的应用
US20230201303A1 (en) * 2020-05-04 2023-06-29 Drugcendr Australia Pty Ltd. Methods for treating pancreatic cancer and other solid tumors
CN115803060A (zh) * 2020-07-10 2023-03-14 (株) 娜迪安生物公司 包含作为活性成分的萘醌基化合物和免疫检查点抑制剂的用于预防或治疗癌症的药物组合物
US20230338363A1 (en) * 2020-08-07 2023-10-26 The Regents Of The University Of California Combination chemo-immunotherapy for pancreatic cancer using the immunogenic effects of an irinotecan silicasome nanocarrier plus anti-pd-1
WO2022055542A1 (en) 2020-09-10 2022-03-17 Nammi Therapeutics, Inc. Formulated and/or co-formulated liposome compositions containing pd-1 antagonist prodrugs useful in the treatment of cancer and methods thereof
KR20230117345A (ko) * 2020-12-01 2023-08-08 더 트러스티스 오브 컬럼비아 유니버시티 인 더 시티 오브 뉴욕 면역조절제를 사용한 면역요법에 대한 암의 민감화 방법
AU2022237225A1 (en) 2021-03-18 2023-10-12 Nammi Therapeutics, Inc. Formulated and/or co-formulated liposome compositions containing a2ar antagonist prodrugs useful in the treatment of cancer and methods thereof
CN113332450B (zh) * 2021-05-11 2023-08-04 铜仁学院 一种眼部给药递释***氧化锌纳米粒的制备方法及其使用方法和应用
CN113353939B (zh) * 2021-05-25 2023-09-08 中国科学院上海硅酸盐研究所 一种带隙可调、降解性可控的二维氢硅烯纳米材料及其制备方法和应用
CN114890385B (zh) * 2021-07-01 2023-09-08 中国科学院上海硅酸盐研究所 一种高效抗氧化二维氢锗烯纳米片及其制备方法和应用
WO2023091168A1 (en) 2021-11-18 2023-05-25 Nammi Therapeutics, Inc. Formulated and/or co-formulated nanocarriers compositions containing immunogenic cell death (icd) inducing prodrugs useful in the treatment of cancer and methods thereof
WO2023172347A1 (en) 2022-03-10 2023-09-14 Nammi Therapeutics, Inc. Formulated and/or co-formulated lipid nanocarriers compositions containing toll-like receptor ("tlr") agonist prodrugs useful in the treatment of cancer and methods thereof
WO2023172300A1 (en) * 2022-03-10 2023-09-14 The Regents Of The University Of California A drug nanocarrier system to deliver a combination of tlr agonists and/or a lipoxin plus immunogenic cell death inducing chemotherapeutic agents for cancer immunotherapy
WO2023183872A1 (en) * 2022-03-23 2023-09-28 You First Services, Inc. Delmopinol and delmopinol salt containing nanoparticles and uses thereof
CN114748414B (zh) * 2022-04-20 2024-05-31 中国医学科学院生物医学工程研究所 一种共负载化疗药和纳米粒的海藻酸钠水凝胶复合体系及其制备方法和应用
CN116327979B (zh) * 2023-05-25 2023-08-01 西南石油大学 一种过渡金属基介孔纳米催化药物、制备方法及用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110159017A1 (en) * 2008-04-11 2011-06-30 Ludwig Institute For Cancer Research Ltd. Trytophan catabolism in cancer treatment and diagnosis
WO2017023667A1 (en) * 2015-07-31 2017-02-09 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Immunostimulatory nanocarrier
WO2018140826A1 (en) * 2017-01-27 2018-08-02 The Methodist Hospital Core/shell structure platform for immunotherapy
WO2019173391A1 (en) * 2018-03-06 2019-09-12 Rita Elena Serda A high capacity platform for immunogenic cancer cell death

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014138278A1 (en) * 2013-03-05 2014-09-12 The Regents Of The University Of California Lipid bilayer coated mesoporous silica nanoparticles with a high loading capacity for one or more anticancer agents
JP7090034B2 (ja) * 2016-05-20 2022-06-23 ザ ユニバーシティ オブ シカゴ 化学療法、標的療法、光線力学療法、免疫療法及びそれらの任意の組み合わせのためのナノ粒子

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110159017A1 (en) * 2008-04-11 2011-06-30 Ludwig Institute For Cancer Research Ltd. Trytophan catabolism in cancer treatment and diagnosis
WO2017023667A1 (en) * 2015-07-31 2017-02-09 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Immunostimulatory nanocarrier
WO2018140826A1 (en) * 2017-01-27 2018-08-02 The Methodist Hospital Core/shell structure platform for immunotherapy
WO2019173391A1 (en) * 2018-03-06 2019-09-12 Rita Elena Serda A high capacity platform for immunogenic cancer cell death

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANU PURI ET AL: "Lipid-Based Nanoparticles as Pharmaceutical Drug Carriers: From Concepts to Clinic", PUBMED CENTRAL (PMC) AUTHOR MANUSCRIPT - HHS PUBLIC ACCESS, 14 June 2010 (2010-06-14), pages 1 - 48, XP055580417, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2885142/> [retrieved on 20190412] *
JING-JING SUN ET AL: "Programmable co-delivery of the immune checkpoint inhibitor NLG919 and chemotherapeutic doxorubicin via a redox-responsive immunostimulatory polymeric prodrug carrier", ACTA PHARMACOLOGICA SINICA, vol. 38, no. 6, 8 May 2017 (2017-05-08), GB, pages 823 - 834, XP055580410, ISSN: 1671-4083, DOI: 10.1038/aps.2017.44 *
See also references of WO2018213631A1 *

Also Published As

Publication number Publication date
AU2018269742A1 (en) 2019-12-05
WO2018213631A1 (en) 2018-11-22
CA3063932A1 (en) 2018-11-12
EP3624810A1 (de) 2020-03-25
AU2018269742B2 (en) 2024-01-11

Similar Documents

Publication Publication Date Title
EP3624810A4 (de) Nano-aktivierte immuntherapie bei krebserkrankungen
IL261163B (en) Methods related to crispr-cpf1, compositions and compositions for cancer immunotherapy
EP3364949A4 (de) Krebsimpfstoffe
EP3286361A4 (de) Krebsneoepitope
EP3240801A4 (de) Kombinationstumorimmuntherapie
EP3280738A4 (de) Krebsneoepitope
EP3226898A4 (de) Bromodomäneninhibitor als adjuvans in der immuntherapie von krebs
EP3250695A4 (de) Universelle immunzellen für krebsimmuntherapie
EP3160497A4 (de) Konjugate für immuntherapie
EP3247408A4 (de) Zusammensetzungen und verfahren für die krebsimmuntherapie
EP3500262A4 (de) Zusammensetzungen und verfahren für die krebsimmuntherapie
EP3703711A4 (de) Zusammensetzungen und verfahren zur behandlung von krebs mit anti-ror1-immuntherapie
EP3474854A4 (de) Krebsbehandlungskombinationen
EP3413927A4 (de) Krebstherapie
EP3597061A4 (de) Büstenhalter
EP3390378A4 (de) Kleine moleküle gegen krebs
EP3202909A4 (de) Krebsspezifisches splicing-ribozym und verwendung davon
EP3292140A4 (de) Immunotherapeutikum gegen krebs
EP3265179A4 (de) Beta-catenin-inhibitoren in der krebsimmuntherapie
EP3347098A4 (de) Abzielung auf mda-5-aktivierung für krebsimmuntherapie
EP3733175A4 (de) Therapeutika gegen krebs
EP3310915A4 (de) Tumorimmuntherapie
EP3638247A4 (de) Zusammensetzungen und verfahren zur verbesserung einer chemotherapie gegen krebs
EP4045054A4 (de) Nano-aktivierte immuntherapie bei krebserkrankungen
EP3294863A4 (de) In vitro

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20191119

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0031711500

Ipc: A61K0047500000

A4 Supplementary search report drawn up and despatched

Effective date: 20210118

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/7115 20060101ALI20210112BHEP

Ipc: A61K 47/69 20170101ALI20210112BHEP

Ipc: A61K 31/7125 20060101ALI20210112BHEP

Ipc: A61K 47/50 20170101AFI20210112BHEP

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230524